Current studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are showing significant results in addressing obesity and related second-type diabetes. Initial evidence suggest a unique action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/